Background: Observational studies with ritual ayahuasca users suggest that experienced users tend to have better cognitive performance, while novice users may experience transient impairments, particularly in working memory. However, no randomized clinical trials have systematically evaluated the cognitive effects of ayahuasca in healthy volunteers. Procedures: This double-blind, randomized,...
Background: Depressive and anxiety symptoms are highly prevalent among patients with cancer and are associated with substantial reductions in quality of life. However, effective therapeutic options remain limited. Ayahuasca, a serotonergic psychedelic traditionally used in Amazonian ritual contexts, has shown rapid antidepressant and anxiolytic effects following a single administration in...
INTRODUCTION: Ibogaine is a natural hallucinogen with emerging evidence for treating substance use disorders. However, its cardiovascular effects are not fully known, and most clinical data focus on opioid dependence, with limited data for Alcohol Use Disorder (AUD). This study assessed the feasibility, safety, and preliminary effects of ibogaine in patients with AUD. METHOD: In this...
Depression is common among patients suffering from cancer, but is often challenging to diagnose due to the overlap of symptoms with cancer and its treatments. Additionally, treating depression in cancer patients is challenging because of the confusion between the adverse effects of antidepressants, cancer treatments, and cancer symptoms. This study aims to evaluate the safety and adverse...
Alcohol is the recreational drug most frequently consumed, and its high frequency of use can lead to worsening social, psychological, and domestic issues. The age group most susceptible to alcohol dependence is 18- to 24-year-old youths, demanding interventional tools to target early involvement risks. Ayahuasca seems to be a promising therapeutic tool since evidence suggests it presents...
Ayahuasca is a South American plant hallucinogen rich in the psychedelic N,N-dimethyltryptamine and β-carbolines (mainly harmine). Preclinical and observational studies suggest that ayahuasca exerts beneficial effects in substance use disorders, but these potentials were never assessed in a clinical trial. Single-center, single-blind, feasibility, proof-of-concept study, assessing the effects...